



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 22024

Title: Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Reviewer's code: 02527608

Reviewer's country: Taiwan

Science editor: Shui Qiu

Date sent for review: 2015-08-11 16:15

Date reviewed: 2015-08-21 13:43

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

1. I suggest that the authors could provide the discrimination between western and eastern therapeutic effects on HCC patients in the table 3.



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 22024

Title: Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Reviewer’s code: 00068209

Reviewer’s country: Japan

Science editor: Shui Qiu

Date sent for review: 2015-08-11 16:15

Date reviewed: 2015-08-24 21:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Comment on the manuscript 22024 by Thillai, et al. Thillai et al comprehensively summarized the current up-date of the genetic abnormality of HCC. The content is timely and useful for clinical and basic researchers of HCC. A total of 5 minor revisions are required for corrections: 1) Next generation sequencing analyses revealed that TERT is the most frequently up-regulated gene due to promoter mutation in HCC. Then authors should refer that TERT is the promising target in “Perspective”. 2) Is the reference ‘13’ in Introduction (page 3, line 31) correct? 3) Cited articles for next generation sequencing are old and the sample number is small. The authors should cite the article by Totoki Y, et al (Nature Genetics, 2014) and Schulze K, et al (Nature Genetics, 2015). 4) In “Underlying liver cirrhosis”, direct acting antivirals drug for HC infection should be referred (as combination therapy in “Perspective”). 5) Clinical trial by anti-PDL1 agent nivolumab might be presented by Anthony B. El-Khoueiry in ASCO 2015. It should be clearly stated.